SCN1A and glioblastoma: In the CNPI, this means editing genes such as SCN1A, DEPDC5, or KCNQ2 in focal epilepsy, or IDH1, TERT, or PTEN in glioblastoma, while also ensuring specificity and limiting collateral damage to the patient [229].